Cited 0 times in
Cited 0 times in
Comparison of High-Dose versus Low-Dose Paclitaxel Drug-Coated Balloons for Native Femoropopliteal Artery Disease: An Analysis of the K-VIS ELLA Registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 민필기 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 이상협 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.date.accessioned | 2025-10-15T02:02:18Z | - |
dc.date.available | 2025-10-15T02:02:18Z | - |
dc.date.issued | 2025-07 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/207552 | - |
dc.description.abstract | Peripheral artery disease ; balloon angioplasty ; paclitaxel ; popliteal artery | - |
dc.description.statementOfResponsibility | T202506287.pdf | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | 0 | - |
dc.title | Comparison of High-Dose versus Low-Dose Paclitaxel Drug-Coated Balloons for Native Femoropopliteal Artery Disease: An Analysis of the K-VIS ELLA Registry | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jaeoh Lee | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Seung-Jun Lee | - |
dc.contributor.googleauthor | Sang-Hyup Lee | - |
dc.contributor.googleauthor | Yong-Joon Lee | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Cheol Woong Yu | - |
dc.contributor.googleauthor | Jae-Hwan Lee | - |
dc.contributor.googleauthor | Seung-Whan Lee | - |
dc.contributor.googleauthor | Young Jin Youn | - |
dc.contributor.googleauthor | Jong Kwan Park | - |
dc.contributor.googleauthor | Chang-Hwan Yoon | - |
dc.contributor.googleauthor | Seung Woon Rha | - |
dc.contributor.googleauthor | Pil-Ki Min | - |
dc.contributor.googleauthor | Seung-Hyuk Choi | - |
dc.contributor.googleauthor | In-Ho Chae | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | K-VIS ELLA investigators | - |
dc.identifier.doi | Purpose: Drug-coated balloons (DCBs) have demonstrated favorable outcomes in the treatment of femoropopliteal artery (FPA) disease. A variety of DCBs are currently available, with differing doses of antiproliferative agents and types of excipients. The objective of this study was to compare the efficacy and safety of high-dose versus low-dose paclitaxel DCBs for the treatment of FPA disease. Materials and methods: We analyzed data from the multicenter the Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA) registry, focusing on patients treated with a high-dose paclitaxel DCB (IN.PACT™) or low-dose paclitaxel DCB (Lutonix™ or Ranger™) for native vessel FPA disease. We used inverse probability of treatment weighting to adjust for confounding factors and conducted subgroup analyses based on lesion characteristics. Results: Among 820 target limbs, 626 were treated with a high-dose paclitaxel DCB, and 194 were treated with a low-dose paclitaxel DCB. At 12 months, there were no significant differences in rates of freedom from clinically driven target lesion revascularization (TLR; 91.7% vs. 89.4%, log-rank p=0.35), major adverse limb event (MALE; 91.4% vs. 89.0%, log-rank p=0.31), or all-cause mortality (93.1% vs. 93.8%, log-rank p=0.79) between high-dose and low-dose groups. On multivariable analysis, the presence of chronic heart failure and chronic kidney disease were the only independent predictors of clinically driven TLR after DCB treatment. Conclusion: In this multicenter cohort study of patients with complex FPA disease, there were no significant differences between high-dose DCB and low-dose DCB with respect to freedom from clinically driven TLR, MALE, or all-cause mortality at 12-month follow-up. | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A01412 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A06152 | - |
dc.contributor.localId | A02927 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 40551590 | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Aged, 80 and over | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Femoral Artery* / pathology | - |
dc.subject.keyword | Femoral Artery* / surgery | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Paclitaxel* / administration & dosage | - |
dc.subject.keyword | Paclitaxel* / therapeutic use | - |
dc.subject.keyword | Peripheral Arterial Disease* / drug therapy | - |
dc.subject.keyword | Popliteal Artery* / drug effects | - |
dc.subject.keyword | Popliteal Artery* / pathology | - |
dc.subject.keyword | Popliteal Artery* / surgery | - |
dc.subject.keyword | Registries | - |
dc.subject.keyword | Treatment Outcome | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 민필기 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 이상협 | - |
dc.contributor.affiliatedAuthor | 이승준 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 66 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 412 | - |
dc.citation.endPage | 420 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.66(7) : 412-420, 2025-07 | - |
dc.identifier.articleno | 10.3349/ymj.2024.0166 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.